+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Europe Pharmaceutical Contract Manufacturing Market - By Type , Country, Trends, Forecasts - 2017 - 2022

  • ID: 4389680
  • Report
  • Region: Europe
  • 85 pages
  • Mordor Intelligence
1 of 3
Contract manufacturing refers to the outsourcing of manufacturing of the products to third party vendors. These pharmaceutical contract manufacturers would be given the chemical formulation of the drug from the pharmaceutical company to manufacture it at their location. Contract manufacturing market is growing significantly since the pharmaceutical companies are focusing more on R & D of the drugs instead of manufacturing the formulated drug to stay competitive in the market. This is driving the pharmaceutical contract manufacturing market.

The Europe Pharmaceutical Contract Manufacturing market is estimated to grow at a compound annual growth rate of 7.33% during the period 2017 - 2022. Extensive use of pharmaceutical contract manufacturing organizations (CMO) began in the 1990s when European drug companies faced increased costs resulting from the expiration of many older drug patents, competition from the generic drug industry and stricter government oversight of new drug development. Drug companies decided to reduce costs by outsourcing many processes previously done in-house, ranging from initial drug research studies to the entire manufacturing process. High costs for drug companies caused by patent expiration, generic drug competition and closer government supervision continue to fuel the growth in the pharmaceutical CMO.

The complaints about rising costs and quality issues connected with Indian and Chinese pharmaceutical CMOs have caused some pharmaceutical companies to stop working with them and instead sign contracts with CMOs operating in Europe. The pharmaceutical CMO marketplace remains highly competitive. Even if some contract manufacturing business is moved back to Europe from India and China, smaller European CMOs competing with Indian and Chinese CMOs may ultimately have to merge with each other, abandon particular specialties within pharmaceutical manufacturing or quit the business completely in order to survive.

The Europe pharmaceutical contract manufacturing market is poised to grow at a CAGR of 9.15% during the period 2016 to 2021. Active Pharmaceutical Ingredient (API) holds the highest market share while final dosage form is estimated to be the top growing segment during the forecasted period. The companies in the upstream industry are undergoing restructuring so as to focus more on R & D and added to this; stringent regulations on the pharmaceutical industry are compelling the companies to outsource the manufacturing of the drugs. Pharmaceutical companies are going for less number of vendors to take volume advantage and at the same time reduce logistics costs.

The Europe pharmaceutical contract manufacturing market has been segmented on the basis of dose formulation type (solid dose formulation, liquid dose formulation and injectable dose formulation), and region (the U.K., Germany, France, Italy and others). This report describes a detailed study of the Porter's five forces analysis of the market. All the five major factors have been quantified using the internal key parameters governing each of them. It also covers the market landscape of these players which includes the key growth strategies, geographical footprint and competition analysis.

The report also considers key trends that will impact the industry and profiles of leading suppliers of pharmaceutical contract manufacturing market. Some of the top companies mentioned in the report are Famar, Recipharm, Jubilant, Vetter, Pfizer CentreSource, Aenova, Catalent, Haupt Pharma, Baxter Bio Pharma Solutions and among others.


The report will be useful in gaining an exhaustive understanding of the regional market. It will also be of assistance in providing a comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.

The report will be an ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.

The report contains a wide range of information about the leading market players and the major strategies adopted by them.
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Study Deliverables
1.2 Key Findings of the Study
1.3 Market Definition
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Current Market Trends
4.2 Drivers
4.2.1 Growing Innovative drugs
4.2.2 Increasing Investments in R&D
4.3 Restraints
4.3.1 In-house packaging
4.3.2 Capacity Utilization Issues Affecting the Profitability of CMOs
4.3.3 Increasing Lead Time & Logistics Costs
4.4 Market Opportunities
4.4.1 Huge Demand for Next Generation Biological Surgeries
4.5 Porters Five Force Analysis
4.5.1 Threat of New Entrants
4.5.2 Bargaining Power of Consumers
4.5.3 Bargaining Power of Suppliers
4.5.4 Threat of Substitute Products and Services
4.5.5 Intensity of Competitive Rivalry
4.6 Industry Value Chain Analysis
4.7 Industry Policies
5. Technology Snapshot
5.1 Dosage Formulation Technologies
5.1.1 Abuse Deterrent Formulation Technology
5.1.2 Lipid Marti-particulate Technology
5.1.3 Dry powder Inhalation Technology
5.1.4 Force Control Agent Technology
5.1.5 High Potency Drug Formulation Technology
5.1.6 Fluidized Bed Coating Technology
5.1.7 Form EZE Technology
5.2 Dosage Forms by Route of Administration
5.2.1 Oral
5.2.2 Topical
5.2.3 Parenteral
5.2.4 Rectal
5.2.5 Vaginal
5.2.6 Inhaled
5.2.7 Ophthalmic
5.2.8 OTIC
6. Europe Pharmaceutical Contract Manufacturing Market Segmentation - By Type
6.1 Active Pharmaceutical Ingredient (API) Manufacturing
6.2 Finished Dosage Formulation (FDF) Development and Manufacturing
6.2.1 Solid Dosage Formulation
6.2.2 Liquid Dose/Semi-Solid Formulation
6.2.3 Injectable Dose Formulation
6.3 Secondary Market
7. Pharma CMO Market -Segmented by geography
7.1 Europe
7.1.1 United Kingdom
7.1.2 Germany
7.1.3 France
7.1.4 Others
8. Europe Pharmaceutical Contract Manufacturing Vendor Market Share
9. Competitive Intelligence - Company Profiles
9.1 Catalent Inc
9.2 Recipharm AB
9.3 Aptiut LLC
9.4 Patheon Inc
9.5 Daito Pharmaceutical
9.6 AbbVie Inc
9.7 Pfizer Centre Source
9.8 Aenova (Haupt) Group
9.9 Famar Inc
9.10 Baxter Bio Pharma Solutions
9.11 Lonza Group
9.12 Contract Pharmaceuticals Limited
9.13 Confab Inc
10. Investment Analysis
10.1 Recent Mergers & Acquisitions
10.2 Investment Scenario and Opportunities
11. Future of Pharmaceutical Contract Manufacturing Market
Note: Product cover images may vary from those shown
3 of 3